Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Expectations By $0.24 EPS

Share on StockTwits

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings results on Sunday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.24), reports. Denali Therapeutics had a negative net margin of 968.59% and a negative return on equity of 39.19%. The company had revenue of $7.90 million during the quarter, compared to analyst estimates of $31.62 million. The firm’s revenue was up 119.4% compared to the same quarter last year.

DNLI stock traded down $2.69 on Tuesday, reaching $55.62. The company’s stock had a trading volume of 727,261 shares, compared to its average volume of 570,040. Denali Therapeutics has a 52 week low of $21.41 and a 52 week high of $93.94. The company has a market capitalization of $6.74 billion, a P/E ratio of -25.17 and a beta of 2.00. The firm has a fifty day moving average of $56.82 and a two-hundred day moving average of $64.76.

Several research firms have recently weighed in on DNLI. Zacks Investment Research raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating and set a $66.00 target price for the company in a research report on Friday, February 19th. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a report on Friday, January 8th. They issued a “positive” rating for the company. Cantor Fitzgerald raised shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating and set a $105.00 target price on the stock in a report on Wednesday, February 10th. HC Wainwright lifted their price target on shares of Denali Therapeutics from $80.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, March 4th. Finally, TheStreet upgraded Denali Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 26th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $74.63.

In related news, insider Carole Ho sold 2,822 shares of the stock in a transaction dated Monday, March 29th. The shares were sold at an average price of $54.62, for a total value of $154,137.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction dated Wednesday, April 28th. The shares were sold at an average price of $62.15, for a total transaction of $103,541.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,449,495 shares of company stock worth $158,540,085. 19.30% of the stock is owned by insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.

Recommended Story: What is a Candlestick Chart?

Earnings History for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.